Sanofi-backed Expedition lands $115M for ph. 2 COPD trial
Expedition Therapeutics raised $115 million to advance its lead oral DPP1 inhibitor EXPD-101 into a global Phase 2 COPD trial.
Expedition Therapeutics
Private
Biotech developing disease-controlling treatments for COPD and other neutrophil-driven inflammatory respiratory diseases. Lead candidate EXPD-101 is an oral, once-daily DPP1 inhibitor advancing into a global Phase 2 COPD trial. Backed by Sanofi.
Company Info
Sector:Biotechnology (respiratory / inflammation)
Headquarters:San Francisco, California, USA
Founded:2024
Website:expeditiontx.com/
Funding Round:Series B
Total Funding:$280M
Funding & Investor Relations
Notable Investors
- Sanofi
- Sofinnova Investments
- Novo Holdings
Clinical Development Pipeline
EXPD-101
Target: DPP1Recent News
Leadership Team
Yi Larson
President and Chief Executive Officer
Eric Hu
Chief Business Officer
Geoff Gilmartin
Chief Medical Officer
Careers & Job Openings